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S U M M A R Y
Background: This phase 3, multi-center, open-label study evaluated the immunogenicity and safety of a
quadrivalent meningococcal conjugate vaccine (MenACWY-CRM, Menveo1; Novartis Vaccines and
Diagnostics S.r.l., Siena, Italy) in healthy Indian subjects aged 2–75 years, to provide data for licensure in
India.
Methods: A total of 180 subjects were enrolled (60 subjects 2–10 years, 60 subjects 11–18 years, and
60 subjects 19–75 years) and received one dose of MenACWY-CRM. Serum bactericidal activity with
human complement (hSBA) was measured before and 1 month after vaccination. Adverse events were
collected throughout the 29-day study period.
Results: Percentages of subjects with post-vaccination hSBA 8 were 72%, 95%, 94%, and 90% for
serogroups A, C, W, and Y, respectively. Geometric mean titers rose 7-fold to 42-fold against the four
serogroups. Similar immune responses were observed for the age subgroups 2–10 years, 11–18 years,
and 19–75 years. Seroresponse rates at 1 month following vaccination were 72%, 88%, 55%, and 71% for
serogroups A, C, W, and Y, respectively. The vaccine was well tolerated with no safety concerns.
Conclusion: A single dose of MenACWY-CRM induced a robust immune response against all four
meningococcal serogroups and was well tolerated in an Indian population 2–75 years of age.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Invasive meningococcal disease is one of the most devastating
global bacterial infections. There are an estimated 500 000 cases of
meningococcal disease every year, causing 50 000 deaths world-
wide.1 The highest rates of disease occur in infants <1 year of age,
and a second peak occurs in adolescents, the population with the
highest carriage.2–4 Meningococcal disease has a high fatality rate
of up to 10% and can lead to death within 24 hours.5 Of those who* Corresponding author. Tel.: +39 0577 539358; fax: +39 0577 245420.
E-mail address: ashwani.k.arora@gsk.com (A. Arora).
http://dx.doi.org/10.1016/j.ijid.2015.07.003
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).survive, 20% endure life-long disabilities such as amputations,
deafness, and neurodevelopmental deﬁcits.6 Based on antigenic
differences in their capsular polysaccharide, at least 12 serogroups
have been identiﬁed. The vast majority of invasive meningococcal
disease (90%) can be attributed to one of six immunologically
distinct serogroups: A, B, C, W-135, X, and Y.6,7
The incidence and serogroup distribution varies with age group
and geographical location, and changes over time. Serogroups B
and C are most prevalent in Europe, Australia, and New Zealand,
serogroups A, C, and W-135 are most common in Asia and Africa,
serogroups B, C, and Y predominate in the USA, Canada, Latin
America, and the Caribbean, and serogroup X has caused sporadic
and clustered meningitis cases in Sub-Saharan Africa.8,9 There isciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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India, however pattern similarities with African epidemics suggest
that serogroup A is predominant.10 Occasional epidemics of
meningococcal disease (mainly serogroup A) in the past century
have been reported, most recently in 2005 in Delhi and
surrounding districts.11 Between March and July 2005, 444 cases
and 62 deaths were recorded.11
MenACWY-CRM (Menveo1; Novartis Vaccines and Diagnostics
S.r.l., Siena, Italy – a GSK company) is a quadrivalent (serogroups A, C,
W-135, and Y) meningococcal polysaccharide conjugate vaccine
that includes Corynebacterium diphtheria cross-reactive material 197
(CRM197) as the carrier protein. Previous clinical studies have shown
that MenACWY-CRM is highly immunogenic against all four
meningococcal serogroups and is well tolerated in a wide range
of age groups, beginning from 2 months of age.12–14MenACWY-CRM
is currently approved in 64 countries. The vaccine has been approved
for use in infants, children, adolescents, and adults, and is also Halal
certiﬁed, which is relevant to many in the Indian population.
When this study was planned, only unconjugated meningococ-
cal polysaccharide vaccines were available in India. Recently, a
quadrivalent meningococcal conjugate vaccine was licensed
(Menactra1; Sanoﬁ Pasteur, Swiftwater, PA, USA). The purpose
of this study is to support licensure of the GSK MenACWY-CRM
vaccine in India. This phase 3, multi-center, open-label study was
designed to evaluate the immunogenicity and safety of a single
dose of the quadrivalent conjugate vaccine, MenACWY-CRM, in
healthy Indian subjects aged 2–75 years.
2. Methods
2.1. Study design and objectives
This phase 3, multi-center, open-label study was conducted at
three study centers in India during the period March 2012 to May
2014 (ClinicalTrials.gov identiﬁer NCT01547715; Clinical Trial
Registry of India identiﬁer CTRI/2012/02/002452). The study was
conducted according to Good Clinical Practice as well as the Ethical
Guidelines for Biomedical Research on Human Subjects issued by
the Indian Council for Medical Research, India. Ethics review
committees approved the study protocol, and written informed
consent was obtained from every participant and their parents or
legal guardians, where appropriate, prior to enrolment. Enrolment
was age-stratiﬁed with de-escalation by age, commencing with
adults, then adolescents, and then children, with interim safety
evaluations of adults and of adolescents.
The immunogenicity objectives of a single dose of MenACWY-
CRM was measured by the percentage of subjects with hSBA
(serum bactericidal activity using human complement) 8, the
seroresponse rate at 1 month after vaccination (day 29) (primary
objective), and hSBA geometric mean titers (GMTs). Immune
responses were assessed as serum bacterial activity using human
complement against Neisseria meningitidis serogroups A, C, W, and
Y. Safety objectives were to assess the number and percentage of
subjects with solicited local and systemic and unsolicited adverse
events (AEs) during the 7 days following vaccination. Serious AEs
(SAEs), medically attended AEs, and AEs leading to premature
study withdrawal were collected throughout the study period,
from day 1 to the end of the study.
2.2. Study participants
A total of 180 subjects were enrolled in this study, 60 in each age
group: 2–10 years, 11–18 years, and 19–75 years. Eligible study
participants were healthy subjects of either sex aged between 2 and
75 years. Female participants of childbearing potential were
required to have a negative urine pregnancy test prior to enrolment.Subjects were excluded from the study if they did not provide
informed consent, if they had a history of any meningococcal vaccine
administration, if they had disease caused by N. meningitidis, or if
there had been intimate exposure to an individual with laboratory
conﬁrmed N. meningitidis. Additional exclusion criteria were a
signiﬁcant infection within 7 days or fever 38 8C within 3 days of
enrolment, known reactions to vaccine components, any serious
chronic or progressive disease, known or suspected immune disease
or impairment, known bleeding diathesis, receipt of blood products,
medical history or illness likely to interfere with the results, receipt
of any vaccine within 14 days (for inactivated vaccines) or 28 days
(for live vaccines) prior to enrollment, or previous receipt (within
28 days before study start) or intent to receive any investigational
agent or vaccines prior to completion of the study.
2.3. Vaccines
MenACWY-CRM was prepared by extemporaneous mixing of the
lyophilized MenA component with the liquid MenCWY component.
Each 0.5-ml vaccine dose contained 10 mg of meningococcal
serogroup A and 5 mg each of capsular polysaccharide of serogroups
C, W-135, and Y conjugated to CRM197. The vaccine was adminis-
tered as an intramuscular injection into the deltoid muscle of the
non-dominant arm.
2.4. Immunogenicity
Blood samples for immunogenicity analyses were obtained on
day 1 (pre-vaccination) and day 29 (1 month post-vaccination).
Immune responses were assessed as hSBA against meningococcal
serogroups A, C, W-135, and Y, according to validated methods, in
the laboratories of GSK Vaccines (Marburg, Germany). Pre- and
post-vaccination antibody responses were expressed as the
percentage of subjects with hSBA 8, percentage of subjects with
a seroresponse, hSBA GMT, and post-vaccination to pre-vaccina-
tion geometric mean ratio (GMR). Seroresponse was deﬁned as a
post-vaccination hSBA 8 in subjects with a pre-vaccination hSBA
<4, and at least 4-fold increase in post-vaccination hSBA in
subjects with a pre-vaccination hSBA 4.
2.5. Safety
Subjects were observed for a minimum of 30 min post-
vaccination to monitor for immediate adverse reactions. Subjects
or guardians recorded solicited AEs and any other AEs on diary
cards for 7 days after the vaccination. In children 2–5 years of age,
injection site tenderness, erythema, and induration, and systemic
reactions such as a change in eating habits, sleepiness, irritability,
vomiting, diarrhea, and rash were collected. In children 6 years of
age and older, injection site pain, erythema, and induration, and
systemic reactions including chills, nausea, malaise, myalgia,
arthralgia, headache, and rash were collected. Body temperature
(fever 38 8C) and use of antipyretic medication was also recorded
for all subjects. Participants were contacted on day 3 post-
vaccination to remind them to complete the diary card.
Serious AEs or AEs resulting in premature withdrawal and other
medically attended events were collected from day 1 to day 29. The
investigators assessed the AEs for seriousness, severity, and
relation to study vaccines. The severity of AEs was categorized
as mild, moderate, or severe, if they resulted in no limitation, some
limitation, or inability to perform normal daily activities,
respectively. Some local AEs such as erythema, induration, and
swelling were categorized based on measurements. Assessments
of the causal relationship of spontaneous AEs to the study vaccines
were classiﬁed as not related, possibly related, or probably related
by the investigator.
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A sample size of 180 subjects aged 2–75 years was considered
adequate to examine the primary study objective (seroresponse
rate), based on the 95% conﬁdence intervals (CI) of the observed
seroresponse. Sixty subjects were planned for enrolment in each
age group. Enrolment was based on a 20% drop-out rate, providing
approximately 144 evaluable subjects for immunogenicity and
approximately 48 subjects in each age group. With 144 subjects, a
95% CI of 42–95% was expected with an observed seroresponse of
50–90%, and with 48 subjects, a 95% CI of 36–99% was expected
with an observed seroresponse of 50–90%. Immunogenicity
endpoints were evaluated descriptively and no formal statistical
hypotheses associated with the immunogenicity objectives of this
study were tested.
Percentages of subjects with hSBA 8, seroresponse (see earlier
deﬁnition), hSBA GMTs, GMRs and corresponding 95% Clopper–
Pearson CI against serogroups A, C, W, and Y were calculated. GMTs
were computed by exponentiating (base 10) least squares means ofTable 1
Study population demographics, by age group and overall populatio
2–10 years 11–18 
n = 60 n = 60 
Age, years, mean  SD 5.77  2.5 14.03
Sex, n (%)
Male 27 (45%) 27 (4
Race, n (%)
Asian 60 (100%) 60 (1
Weight, kg, mean  SD 18.87  5.81 41.08
Height, cm, mean  SD 112.47  15.65 152.73
Met entry criteria, n (%)
Yes 60 (100%) 58a (9
SD, standard deviation.
a Two females did not satisfy entry criteria as a pregnancy test w
2 to 10 years (N=58-60) 11 to 18 years (N=59-60) 
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Figure 1. Percentage of subjects (95% conﬁdence interval) with hSBA 8 at baseline (day
group and overall population.the logarithmically transformed titers. Titers below the limit of
detection would be set to half that limit for the purposes of
analysis.
Safety data were evaluated descriptively and expressed as the
number or percentage of subjects with AEs in each age group.
Immunogenicity analyses were run on the full analyses set
(FAS), which consisted of subjects who provided at least one
evaluable serum whose assay result was available for at least one
serogroup. Safety was analyzed for all subjects exposed to the
study vaccine who provided safety data. All statistical analyses
were performed using SAS1 version 9.2 (SAS Institute, Cary, NC,
USA).
3. Results
A total of 180 subjects were enrolled, 60 subjects within each
age subgroup. All enrolled subjects received a single dose of
MenACWY-CRM and completed the study with no premature
withdrawals. The baseline demographics of the enrolled subjectsn
years 19–75 years Overall
n = 60 n = 180
  1.931 32.67  12.297 17.49  13.432
5%) 39 (65%) 93 (51.7%)
00%) 60 (100%) 180 (100%)
  11.84 61.25  10.64 40.4  19.9
  11.62 164.6  9.24 143.27  25.57
6.7%) 60 (100%) 178 (98.9%)
as not performed prior to vaccination.
19 to 75 years (N=58-60) Overall (N=177-179) 
Day 1 Day 29 Day 1 Day 29 
Serogroup W Serogroup Y 
 
52 
63 
59 
58 
 95  95  93  94 
 22 
 53  53 
 42 
 83 
 95  93 
 90 
 1) and 1 month post-vaccination (day 29) against serogroups A, C, W, and Y, by age
Table 2
Seroresponse rates (95% conﬁdence interval) against serogroups A, C, W, and Y at 1 month post-vaccination (day 29), by age group and overall populationa
2–10 years 11–18 years 19–75 years Overall
n = 60 n = 59 n = 58 n = 177
Serogroup A
hSBA <1:4 74 (61–85), n = 58 76 (63–86), n = 58 65 (51–770), n = 57 72 (64–78), n = 173
hSBA 1:4 100 (16–100), n = 2 100 (3–100), n = 1 100 (3–100), n = 1 100 (40–100), n = 4
Overall 75 (62–85) 76 (63–86) 66 (52–78) 72 (65–79)
Serogroup C
hSBA <1:4 90 (77–97), n = 48 95 (82–99), n = 38 94 (81–99), n = 36 93 (86–97), n = 122
hSBA 1:4 60 (26–88), n = 10 81 (58–95), n = 21 82 (60–95), n = 22 77 (64–8), n = 53
Overall 84 (73–93), n = 58 90 (79–96) 90 (79–96) 88 (82–92), n = 175
Serogroup W
hSBA <1:4 88 (69–97), n = 25 90 (70–99), n = 21 86 (65–97), n = 22 88 (78–95), n = 68
hSBA 1:4 37 (21–55), n = 35 29 (15–46), n = 38 34 (19–52), n = 35 33 (25–43), n = 108
Overall 58 (45–71) 51 (37–64) 54 (41–68), n = 57 55 (47–62), n = 176
Serogroup Y
hSBA <1:4 76 (61–88), n = 42 89 (71–98), n = 27 92 (73–99), n = 24 84 (75–91), n = 93
hSBA 1:4 50 (25–75), n = 16 53 (35–71), n = 32 64 (45–80), n = 33 57 (45–68), n = 81
Overall 69 (55–80), n = 58 69 (56–81) 75 (62–86), n = 57 71 (64–78), n = 174
hSBA, serum bactericidal activity assay using human complement.
a Seroresponse was deﬁned as a post-vaccination hSBA 8 for subjects with a pre-vaccination hSBA <4, and an increase in hSBA titer of at least four times the pre-
vaccination titer for subjects with a pre-vaccination hSBA 4.
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across age groups, except for a predominance of male participants
aged 19–75 years; all subjects were of Asian origin.
3.1. Immunogenicity
At day 1 before MenACWY-CRM vaccination, the percentage of
overall subjects who had baseline hSBA 8 was 1%, 21%, and 42%
for serogroups A, C, and Y, respectively, whereas the majority of
subjects (58%) had a baseline hSBA 8 for serogroup W (Figure 1).
At day 29 post-vaccination, the percentages of subjects with hSBA
8 were 72%, 95%, 94%, and 90% for serogroups A, C, W, and Y,
respectively (Figure 1).
In the overall population, the seroresponse rate at 1 month
following a single vaccination of MenACWY-CRM was 72%, 88%,
55%, and 71% against serogroups A, C, W, and Y, respectively
(Table 2). Among those with a baseline hSBA <4, the seror-
esponse rate was 72%, 93%, 88%, and 84% for serogroups A, C, W,
and Y, respectively. For the subjects with a baseline hSBA 4, the
seroresponse rate was 100%, 77%, 33%, and 57% for serogroups A,
C, W, and Y, respectively. Comparatively few subjects were
included for immunogenicity analysis for serogroup A at baseline
hSBA 4 (n = 4), as compared with serogroups C (n = 53), WTable 3
hSBA geometric mean titers (95% conﬁdence interval) against serogroups A, C, W, and 
population
2–10 years 11–18 years 
n = 60 n = 60 
Serogroup A
Day 1 2.08 (1.97–2.20) 2.05 (1.95–2.16
Day 29 30 (19–47) 50 (30–84) 
Serogroup C
Day 1 2.88 (2.26–3.65) 4.01 (3.00–5.35
Day 29 67 (44–101) 191 (117–310) 
Serogroup W
Day 1 9.27 (6.33–14) 14 (9.13–20) 
Day 29 60 (44–81) 75 (54–105) 
Serogroup Y
Day 1 3.59 (2.75–4.7) 7.87 (5.48–11)
Day 29 30 (19–47) 105 (72–155) 
hSBA, serum bactericidal activity assay using human complement.(n = 108), and Y (n = 81). There was an overall increase in
seroresponse against serogroups W and Y when stratiﬁed by
baseline hSBA <4.
Baseline GMTs in the overall population ranged between
2.07 and 11 for serogroups A, C, W, and Y. At 1 month after a single
dose of MenACWY-CRM, there were substantial increases in GMT,
as evidenced by a 17-fold GMT increase over baseline against
serogroup A, a 42-fold increase against serogroup C, a 7-fold
increase against serogroup W, and a 15-fold increase against
serogroup Y. Generally, an increase in post-vaccination GMTs was
noted with increasing age (Table 3).
3.2. Safety
All enrolled subjects exposed to study vaccination contributed
to the safety analyses. Overall, MenACWY-CRM was well tolerated
across all age groups. A low incidence of solicited AEs was reported
for subjects aged 2–5 years (3.3%) as compared to subjects aged 6–
75 years (25.3%). The most commonly reported solicited local
reaction was tenderness (3.3%) in the 2–5 years age group, and pain
(17.3%) in the 6–75 years age group. None of the subjects in the
overall population developed erythema or induration, and there
were no severe local reactions (Table 4).Y at baseline and at 1 month post-vaccination (day 29), by age group and overall
19–75 years Overall
n = 60 n = 180
) 2.07 (1.93–2.21) 2.07 (2.00–2.14)
29 (16–51) 35 (26–47)
) 4.14 (3.12–5.49) 3.63 (3.11–4.25)
287 (191–431) 153 (117–199)
12 (7.70–17) 11 (9.05–14)
116 (71–187) 80 (64–100)
 8.69 (5.98–13) 6.26 (5.13–7.65)
173 (97–309) 93 (70–123)
Table 4
Number (%) of subjects experiencing any and severe solicited local reactions within 7 days after MenACWY-CRM vaccination, by age group and overall populationa
6–10 years 11–18 years 19–75 years Overall
n = 30 n = 60 n = 60 n = 150
Erythema (mm) Any 0 (0%) 0 (0%) 0 (0%) 0 (0%)
>100 mm 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Induration (mm) Any 0 (0%) 0 (0%) 0 (0%) 0 (0%)
>100 mm 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Pain Any 4 (13.3%) 17 (28.3%) 5 (8.3%) 26 (17.3%)
2–5 years, n = 30
Erythema (mm) Any 0 (0%)
>50 mm 0 (0%)
Induration (mm) Any 0 (0%)
>50 mm 0 (0%)
Tenderness Any 1 (3.3%)
a Severe erythema and induration classiﬁed as >50 mm in the age group 2–5 years, and >100 mm in the age group 6–75 years.
Table 5
Number (%) of subjects experiencing any and severe solicited systemic reactions within 7 days after MenACWY-CRM vaccination, by age group and overalla
6–10 years 11–18 years 19–75 years Overall
n = 30 n = 60 n = 60 n = 150
Arthralgia Any 1 (3.3%) 1 (1.7%) 0 (0%) 2 (1.3%)
Severe 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Chills Any 0 (0%) 4 (6.7%) 2 (3.3%) 6 (4%)
Severe 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Headache Any 2 (6.7%) 5 (8.3%) 7 (11.7%) 14 (9.3%)
Severe 0 (0%) 1 (1.7%) 0 (0%) 1 (0.7%)
Malaise Any 2 (6.7%) 2 (3.3%) 2 (3.3%) 6 (4%)
Severe 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Myalgia Any 1 (3.3%) 0 (0%) 2 (3.3%) 3 (2%)
Severe 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Nausea Any 0 (0%) 1 (1.7%) 1 (1.7%) 2 (1.3%)
Severe 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Fever (38.0 8C) Yes 1 (3.3%) 1 (1.7%) 1 (1.7%) 3 (2%)
Other
Use of analgesics/antipyretics 2 (6.7%) 5 (8.3%) 2 (3.3%) 9 (6%)
Temperature, 8C
<38.0 29 (96.7%) 59 (98.3%) 59 (98.3%) 147 (98%)
38.0–39.0 1 (3.3%) 1 (1.7%) 1 (1.7%) 3 (2.0%)
>40 0 (0%) 0 (0%) 0 (0%) 0 (0%)
a In subjects 2–5 years of age, none reported systemic reactions (change in eating habits, sleepiness, irritability, vomiting, diarrhea, rash), body temperature 38.0 8C, or use
of analgesics/antipyretics.
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solicited systemic reactions and there were no reports of fever
38 8C or use of analgesics and antipyretics. In the age group 6–10
years, the most commonly reported systemic reactions were
headache (6.7%) and malaise (6.7%). In the age group 11–18 years,
the most common systemic reaction was headache (8.3%), and one
subject reported a severe headache on day 4 after vaccination. In
the age group 19–75 years, the most common reaction was also
headache (11.7%). A temperature of 38 8C was reported in three
subjects (2%), there were no reports of high fever 40 8C, and 6% of
subjects reported use of analgesics/antipyretics (Table 5).
Overall, unsolicited reactions were reported by 10.6% of
subjects, of which 2.8% were considered at least possibly related
to study vaccination as determined by the investigator.
During the 29-day study period, there was one SAE (pyrexia),
which was considered at least possibly related to study vaccina-
tion. A 34-year-old woman experienced a mild fever, chills,
headache, and body-aches 1 day after vaccination. The woman was
admitted to hospital to rule out the possibility of malaria. The
laboratory tests were negative for malarial parasites and the
discharge diagnosis was fever with chills. The subject recovered
completely after 3 days. The assessment of a possible relationship
between the SAE and the vaccine was based on a temporal
relationship to vaccination. Medication was prescribed for AEsreported in 9.4% of subjects (13.3%, 8.3%, and 6.7% in those aged
2–10 years, 11–18 years, and 19–75 years, respectively). None of
the subjects withdrew prematurely from the study due to an AE.
There were no deaths.
4. Discussion
Invasive meningococcal disease is a severe, but potentially
preventable, healthcare problem worldwide. Vaccines against
more than one serogroup have been developed to help provide
broader protection against the disease. This phase 3, multi-center,
open-label study was the ﬁrst to evaluate the immunogenicity and
safety of a single dose of investigational MenACWY-CRM in healthy
Indian subjects aged 2–75 years.
The results demonstrate that MenACWY-CRM induced a robust
immune response against all four meningococcal serogroups and
was well tolerated within a wide range of age groups. The
commonly accepted surrogate endpoint for protection against
meningococcal disease is hSBA 4.15 However, the secondary
objective was deﬁned using the even more conservative endpoint
of hSBA 8 to be consistent with other studies conducted globally.
The immunogenic response of a single dose of MenACWY-CRM
was demonstrated by the percentage of subjects achieving hSBA
8 (72%, 95%, 94%, and 90% for serogroups A, C, W, and Y,
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subgroups 2–10 years, 11–18 years, and 19–75 years.
Regardless of baseline serostatus, the percentages of subjects
achieving seroresponse at 1 month following vaccination were
72%, 88%, 55%, and 71% for serogroups A, C, W, and Y, respectively.
Finally, pre-vaccination GMTs increased 17-fold against ser-
ogroup A, 42-fold against serogroup C, 7-fold against serogroup W,
and 15-fold against serogroup Y. The observed post-vaccination
GMTs were generally somewhat higher with increasing age, which
has been noted previously.16,17
The seroresponse rates of meningococcal serogroups A, C, and Y
are in accordance with the pivotal clinical studies used for
licensure of MenACWY-CRM in Europe and the rest of the
world.12,14,16 The rate of subjects 2–10 years of age achieving a
seroresponse against serogroups A, C, and Y was 74%, 61%, and
62%,16 which is in agreement with 75%, 84%, and 69% observed for
this age group in the present study. For the adolescents aged 11–18
years, the rate of seroresponse against A, C, and Y was 58%, 68%, and
47%,12 as compared with 76%, 90%, and 69% in the present study. In
adults aged 19–55 years, the previously observed percentages of
seroresponders following MenACWY-CRM vaccination for ser-
ogroups A, C, and Y were 67%, 67%, and 56%,14 compared with the
observed 66%, 90%, and 75% in the present study.
Of note, a high percentage of subjects had a pre-vaccination
hSBA 8 against serogroup W (58% overall). Recently published
studies conducted in Russia, Thailand, and Korea obtained similar
results.17–19 Potential reasons for the high pre-vaccination
bactericidal antibodies against serogroup W may include nasal
colonization or antibody priming with cross-reactive antigens
induced by non-meningococcal bacteria.19 However, the percent-
age of subjects achieving hSBA 8 at 1 month following
vaccination was high (94% overall).
In agreement with previous studies in children,16,20 adoles-
cents,12,21 and adults,14,22 the safety data demonstrated that
MenACWY-CRM was well tolerated and no safety concerns were
identiﬁed. A low incidence of solicited AEs was reported for
subjects 2–5 years of age (3.3%) as compared to subjects aged 6–75
years (25.7%). There were no solicited systemic AEs in the 2–5
years age group, and only transient and mild to moderate solicited
local reactions occurred within the studied population. During the
study period, one SAE occurred (pyrexia), for which the assessment
of a possible relationship with the vaccine was based on time
proximity to vaccination.
Until recently, only unconjugated meningococcal polysaccha-
ride vaccines were licensed in India. Such vaccines can induce a
T-cell-independent response for which the duration of the
protection is limited, especially in younger age groups, and
immune hyporesponsiveness to subsequent doses has been
described.23,24 An advantage of conjugate meningococcal vac-
cines is that they can induce a robust T-cell-dependent response
and immunological memory, which is believed to be associated
with longer lasting immunity.25 Also, meningococcal conjugate
vaccines reduce asymptomatic carriage of N. meningitidis, which
is an important contributor to herd immunity.26 The MenACWY-
CRM vaccine is also Halal certiﬁed, which is relevant to the Indian
population.
As a limitation, this study did not include a vaccine comparator
or placebo arm. However, previous pivotal trials covering a wide
range of age groups have compared MenACWY-CRM with a
quadrivalent polysaccharide vaccine and other available conjugat-
ed quadrivalent vaccines, and have reported MenACWY-CRM to
be non-inferior and well tolerated with a satisfactory safety
proﬁle.12,14,16
Overall, a single dose of MenACWY-CRM was well tolerated and
elicited a robust immune response against all four serogroups in
children, adolescents, and adults in India.Acknowledgements
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